These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 34274891)
21. A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA). Hahn CD; Jiang Y; Villanueva V; Zolnowska M; Arkilo D; Hsiao S; Asgharnejad M; Dlugos D Epilepsia; 2022 Oct; 63(10):2671-2683. PubMed ID: 35841234 [TBL] [Abstract][Full Text] [Related]
22. A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication. Strzelczyk A; Schubert-Bast S CNS Drugs; 2022 Mar; 36(3):217-237. PubMed ID: 35156171 [TBL] [Abstract][Full Text] [Related]
23. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results. Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A; Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635 [TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of six new antiseizure medications for adjunctive treatment of focal epilepsy and epileptic syndrome: A systematic review and network meta-analysis. Tong J; Ji T; Liu T; Liu J; Chen Y; Li Z; Lu N; Li Q Epilepsy Behav; 2024 Mar; 152():109653. PubMed ID: 38277848 [TBL] [Abstract][Full Text] [Related]
25. Stiripentol for the treatment of seizures in Dravet syndrome. Eschbach K; Knupp KG Expert Rev Clin Pharmacol; 2019 May; 12(5):379-388. PubMed ID: 31017478 [TBL] [Abstract][Full Text] [Related]
26. Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. Wijnen B; Witlox W; Wolff R; Fayter D; Ramaekers B; Otten T; Ryder S; Posadzki P; Worthy G; Stirk L; Armstrong N; Kleijnen J; Joore M Pharmacoeconomics; 2023 Jan; 41(1):33-42. PubMed ID: 36301414 [TBL] [Abstract][Full Text] [Related]
27. Therapeutic advances in Dravet syndrome: a targeted literature review. Strzelczyk A; Schubert-Bast S Expert Rev Neurother; 2020 Oct; 20(10):1065-1079. PubMed ID: 32799683 [TBL] [Abstract][Full Text] [Related]
28. Fenfluramine treatment is associated with improvement in everyday executive function in preschool-aged children (<5 years) with Dravet syndrome: A critical period for early neurodevelopment. Bishop KI; Isquith PK; Gioia GA; Knupp KG; Scheffer IE; Nabbout R; Specchio N; Sullivan J; Auvin S; Helen Cross J; Guerrini R; Farfel G; Galer BS; Gammaitoni AR Epilepsy Behav; 2023 Jan; 138():108994. PubMed ID: 36463826 [TBL] [Abstract][Full Text] [Related]
30. Short-term and long-term efficacy and safety of antiseizure medications in Lennox Gastaut syndrome: A network meta-analysis. Devi N; Madaan P; Ameen R; Sahu JK; Bansal D Seizure; 2022 Jul; 99():164-175. PubMed ID: 35487871 [TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: A real-world study. Specchio N; Pietrafusa N; Doccini V; Trivisano M; Darra F; Ragona F; Cossu A; Spolverato S; Battaglia D; Quintiliani M; Luigia Gambardella M; Rosati A; Mei D; Granata T; Dalla Bernardina B; Vigevano F; Guerrini R Epilepsia; 2020 Nov; 61(11):2405-2414. PubMed ID: 32945537 [TBL] [Abstract][Full Text] [Related]
32. Stiripentol: A Novel Antiseizure Medication for the Management of Dravet Syndrome. Buck ML; Goodkin HP Ann Pharmacother; 2019 Nov; 53(11):1136-1144. PubMed ID: 31167540 [No Abstract] [Full Text] [Related]
33. Safety considerations selecting antiseizure medications for the treatment of individuals with Dravet syndrome. Nabbout R; Chemaly N; Chiron C; Kuchenbuch M Expert Opin Drug Saf; 2021 May; 20(5):561-576. PubMed ID: 33645379 [No Abstract] [Full Text] [Related]
34. Time to onset of cannabidiol treatment effects in Dravet syndrome: Analysis from two randomized controlled trials. Madan Cohen J; Checketts D; Dunayevich E; Gunning B; Hyslop A; Madhavan D; Villanueva V; Zolnowska M; Zuberi SM Epilepsia; 2021 Sep; 62(9):2218-2227. PubMed ID: 34265088 [TBL] [Abstract][Full Text] [Related]
35. Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: A multicenter, open-label study in Japan. Inoue Y; Ohtsuka Y; Epilepsy Res; 2015 Jul; 113():90-7. PubMed ID: 25986195 [TBL] [Abstract][Full Text] [Related]
36. Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome. Devinsky O; Cross JH; Laux L; Marsh E; Miller I; Nabbout R; Scheffer IE; Thiele EA; Wright S; N Engl J Med; 2017 May; 376(21):2011-2020. PubMed ID: 28538134 [TBL] [Abstract][Full Text] [Related]
37. Stiripentol in Dravet syndrome: results of a retrospective U.S. study. Wirrell EC; Laux L; Franz DN; Sullivan J; Saneto RP; Morse RP; Devinsky O; Chugani H; Hernandez A; Hamiwka L; Mikati MA; Valencia I; Le Guern ME; Chancharme L; de Menezes MS Epilepsia; 2013 Sep; 54(9):1595-604. PubMed ID: 23848835 [TBL] [Abstract][Full Text] [Related]